Search
Norethindrone enanthate
go.drugbank.com/drugs/DB14678InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDextrorphan
go.drugbank.com/drugs/DB14682ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and i...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigationalFidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-mem...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2D6 InhibitorsPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand nam...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalSofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-strand...
Categories: P-glycoprotein substrates